Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 3 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Kytril — KYTRIL
Application NDA021238 (NDA)
Virazole — COPEGUS
Application NDA021511 (NDA)
Virazole — REBETOL
Application NDA021546 (NDA)
Boniva — BONIVA
Application NDA021455 (NDA)
Fuzeon — FUZEON
Application NDA021481 (NDA)
Kytril — KYTRIL
Application NDA020239 (NDA)
Rocephin — CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER
Application NDA050796 (NDA)
Boniva — BONIVA
Application NDA021858 (NDA)
Tamiflu — TAMIFLU
Application NDA021087 (NDA)
Kytril — SANCUSO
Application NDA022198 (NDA)
Zelboraf — ZELBORAF
Application NDA202429 (NDA)
Tamiflu — TAMIFLU
Application NDA021246 (NDA)
Accutane — ABSORICA
Application NDA021951 (NDA)
Kytril — SUSTOL
Application NDA022445 (NDA)
Versed — SEIZALAM
Application NDA209566 (NDA)
Accutane — ABSORICA LD
Application NDA211913 (NDA)
Versed — NAYZILAM
Application NDA211321 (NDA)
Versed — MIDAZOLAM IN 0.9% SODIUM CHLORIDE
Application NDA211844 (NDA)
Versed — MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)
Application NDA216359 (NDA)
Versed — MIDAZOLAM IN 0.8% SODIUM CHLORIDE
Application NDA215868 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)